Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Research & Development Ltd
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A study of mepolizumab in children from 6 to 11 years of age with severe asthma
Pharmacokinetic/Pharmacodynamic Phase (Part A) - To characterize the pharmacokinetics of mepolizumab administered subcutaneously to subjects aged 6 to 11 years old with severe eosinophilic asthma...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
Dose ranging study for GSK233705B delivered once daily in subjects with COPD
The primary objective of this study is to evaluate the dose response, efficacy, and safety of five dosage regimens of GSK233705B (12.5, 25, 50, 100 and 200mcg once daily), compared with placebo, in su...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
Evaluation of Nelarabine in two patient populations
T o evaluate the safety and tolerability of nelarabine administered to Japanese patients with T-ALL or TLBL as a 2-hour intravenous infusion on a Day 1, 3 and 5 schedule for adult patients and as a 1-...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy versus Trastuzumab Plus Chemotherapy as Firstline Treatment for Women with HER2-positive and p95HER2-positive Metastatic Breast Cancer
The primary endpoint of this study is progression-free survival (PFS) and is defined as the interval between date of randomization and disease progression or death from any cause.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
English Study evaluating safety and efficacy of mepolizumab in the treatment of COPD patients with frequent exacerbations
To evaluate the efficacy and safety of mepolizumab 100 mg and 300 mg subcutaneous (SC) given every 4 weeks compared to placebo on the frequency of moderate and severe exacerbations in COPD subjects at...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A phase 3 pharmacokinetic study in healthy volunteers of mepolizumab as liquid formulation versus powder for solution formulation
To compare the pharmacokinetics of subcutaneous mepolizumab following a single dose of the. liquid drug product in safety syringe with the lyophilized drug product To compare the pharmacokinetics ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of the H3 receptor antagonist, GSK239512 in subjects with mild to moderate Alzheimer’s disease
• To assess the efficacy of GSK239512 on cognitive function in subjects with mild to moderate Alzheimer’s disease after 16 weeks of treatment
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
12-week study to compare two treatments in an inhaler with two treatments in separate inhalers in patients with chronic obstructive pulmonary disease
The primary objective of this study is to demonstrate that UMEC/VI, when used in symptomatic moderate to very severe COPD subjects, is non-inferior to the combination of indacaterol plus tiotropium, a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A Comparison of Fluticasone Furoate Nasal Spray (FFNS) versus Oral Fexofenadine in the Treatment of Seasonal Allergies
The primary objective of this study was to demonstrate that FFNS provides superior nighttime symptom relief over fexofenadine.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination with Vinorelbine or Capecitabine in Women with ErbB2 Overexpressing Metastatic Breast Cancer
• To evaluate progression-free survival (PFS) in women with ErbB2-overexpressing MBC treated with lapatinib in combination with vinorelbine or lapatinib in combination with capecitabine, who have rece...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant